Cambrex Co. (CBM) COO Sells $254,514.40 in Stock

Share on StockTwits

Cambrex Co. (NYSE:CBM) COO Shawn Cavanagh sold 6,769 shares of the company’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $37.60, for a total value of $254,514.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

CBM opened at $40.19 on Friday. The company has a current ratio of 3.93, a quick ratio of 2.86 and a debt-to-equity ratio of 0.46. The firm has a market cap of $1.29 billion, a P/E ratio of 14.51, a P/E/G ratio of 1.29 and a beta of 2.45. Cambrex Co. has a 52 week low of $33.80 and a 52 week high of $69.43.

Cambrex (NYSE:CBM) last posted its quarterly earnings data on Wednesday, February 13th. The biotechnology company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.32 by $0.12. The business had revenue of $212.30 million for the quarter, compared to analyst estimates of $182.49 million. Cambrex had a return on equity of 14.74% and a net margin of 17.37%. The business’s revenue for the quarter was up 16.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.26 earnings per share. Equities analysts predict that Cambrex Co. will post 2.97 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of CBM. BlackRock Inc. lifted its position in Cambrex by 3.2% during the fourth quarter. BlackRock Inc. now owns 4,885,273 shares of the biotechnology company’s stock worth $184,469,000 after buying an additional 153,664 shares during the period. Vanguard Group Inc lifted its position in Cambrex by 3.2% during the third quarter. Vanguard Group Inc now owns 3,282,272 shares of the biotechnology company’s stock worth $224,507,000 after buying an additional 101,303 shares during the period. Vanguard Group Inc. lifted its position in Cambrex by 3.2% during the third quarter. Vanguard Group Inc. now owns 3,282,272 shares of the biotechnology company’s stock worth $224,507,000 after buying an additional 101,303 shares during the period. William Blair Investment Management LLC lifted its position in Cambrex by 9.9% during the third quarter. William Blair Investment Management LLC now owns 2,530,397 shares of the biotechnology company’s stock worth $173,079,000 after buying an additional 228,059 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Cambrex by 10.2% during the fourth quarter. Bank of New York Mellon Corp now owns 1,654,842 shares of the biotechnology company’s stock worth $62,487,000 after buying an additional 153,406 shares during the period.

A number of analysts recently commented on CBM shares. Jefferies Financial Group lowered Cambrex from a “buy” rating to a “hold” rating in a research note on Friday. ValuEngine raised Cambrex from a “strong sell” rating to a “sell” rating in a research note on Friday. Zacks Investment Research lowered Cambrex from a “buy” rating to a “hold” rating in a research note on Friday, February 1st. TheStreet lowered Cambrex from a “b” rating to a “c+” rating in a research note on Monday, December 3rd. Finally, Robert W. Baird started coverage on Cambrex in a research note on Thursday, November 15th. They set an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $56.88.

WARNING: This report was first reported by Zolmax and is the property of of Zolmax. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://zolmax.com/investing/cambrex-co-cbm-coo-sells-254514-40-in-stock/2919782.html.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.

Recommended Story: New Google Finance Tool and Screening Stocks

Insider Buying and Selling by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Great West Life Assurance Co. Can Raises Position in Olin Co.
Great West Life Assurance Co. Can Raises Position in Olin Co.
Great West Life Assurance Co. Can Buys 1,272 Shares of Navigators Group Inc
Great West Life Assurance Co. Can Buys 1,272 Shares of Navigators Group Inc
Insider Selling: salesforce.com, inc.  General Counsel Sells 5,259 Shares of Stock
Insider Selling: salesforce.com, inc. General Counsel Sells 5,259 Shares of Stock
Stuart Depina Sells 18,168 Shares of Envestnet Inc  Stock
Stuart Depina Sells 18,168 Shares of Envestnet Inc Stock
PerkinElmer, Inc.  Shares Bought by Great West Life Assurance Co. Can
PerkinElmer, Inc. Shares Bought by Great West Life Assurance Co. Can
Citigroup Inc. Trims Position in Goldman Sachs ActiveBeta Emerging Markets Equity ETF
Citigroup Inc. Trims Position in Goldman Sachs ActiveBeta Emerging Markets Equity ETF


 
© 2006-2019 Zolmax.